Exclude Patient Type Detail Header
Yes
Footnote
<sup>1</sup> Fiasp. Prescribing information. Novo Nordisk Inc.; 2022.<br><br>
<sup>2</sup> Afrezza. Prescribing information. MannKind Corporation; 2023.<br><br>
<sup>3</sup> Eli Lilly and Company. Humulin R U-500 human insulin monotherapy delivers a dual action, providing the properties of both basal and mealtime coverage when dosed as directed. Humulin R U-500 website. Accessed July 28, 2023. <a href=https://www.humulin.com/hcp/dosing-titration#insulin-activity><u>https://www.humulin.com/hcp/dosing-titration#insulin-activity</u></a>.
<sup>2</sup> Afrezza. Prescribing information. MannKind Corporation; 2023.<br><br>
<sup>3</sup> Eli Lilly and Company. Humulin R U-500 human insulin monotherapy delivers a dual action, providing the properties of both basal and mealtime coverage when dosed as directed. Humulin R U-500 website. Accessed July 28, 2023. <a href=https://www.humulin.com/hcp/dosing-titration#insulin-activity><u>https://www.humulin.com/hcp/dosing-titration#insulin-activity</u></a>.
Detail Type
Image
Detail Image
Patient Type Detail Header (Long)
Rapid-acting and regular insulin switches